We claim:

1. A compound of the formula (I):



I

wherein

A is CH or N;

n is 1 or 2;

when n is 1, y is 0 or 2;

when n is 2, y is 0;

g is 1 or 2;

each R_3 is independently hydrogen, C_1-C_6alkyl, or



wherein w is 1, 2, or 3;

R is selected from the group consisting of (a) – (w):

a) 

b) 

c) 

d) 

e) 

f) 

g) 

h) 

i) 

j) 

k) 

l) 

m) $-CO_2R_{16}$

n) 

o)



p)



q)



r)



s)



t)



u)



v)



w)



wherein

each R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11}, R_{12} and R_{18} is independently hydrogen, C_1-C_6alkyl, halogen, trifluoromethyl, -CO_2C_1-C_6alkyl or -CH_2OC_1-C_6alkyl;

each R_{71}, R_{72}, R_{74} and R_{80} is independently hydrogen, C_1-C_6alkyl, C_1-C_6alkoxy, halogen, trifluoromethyl, -CO_2C_1-C_6alkyl or -CH_2OC_1-C_6alkyl;

R_{73} is hydrogen, alkyl, pyridyl, benzyl, $-CH_2CF_3$, $-CO_2C_1$-C_6alkyl, phenyl optionally substituted with halogen, trifluoromethyl, trifluoromethoxy or R_{73} is



wherein w is 1, 2 or 3 as hereinbefore defined;

each R_{75} is hydrogen, halogen, C_1-C_6alkyl or C_1-C_6alkoxy;

each R_{76} is hydrogen, halogen, -CN or C_1-C_6alkyl;

each R_{77} is hydrogen, halogen, C_1-C_6alkyl or C_1-C_6alkoxy;

each R_{78} hydrogen, halogen, C_1-C_6alkyl or C_1-C_6alkoxy;

each R_{79} hydrogen, halogen, C_1-C_6alkyl or C_1-C_6alkoxy;

p, s and x are 0, 1, or 2;

each R_{13} is independently hydrogen, C_1-C_6alkyl, halogen, benzyl, trifluoromethyl, C_1-C_6alkoxy, nitro, -CN, or $-COC_1$-C_6alkyl;

R_{16} is C_1-C_6alkyl;

each R_{14} and R_{15} is independently hydrogen or C_1-C_6alkyl;

R_{17} is hydrogen, C_1-C_6alkyl, Ar, -COAr, -CONHAr or $-SO_2$-Ar wherein Ar is a phenyl group which is optionally mono- or di-substituted with substituents independently selected from C_1-C_6alkyl, halogen, trifluoromethyl, C_1-C_6alkoxy, nitro, CN and COC_1-C_6alkyl; and

m is 0, 1, or 2;



represents a group selected from (a) - (f):

a) 

b)



(c)



(d)



(e)



(f)

wherein

each R_{19} and R_{20} is independently hydrogen, hydroxy or C_1-C_6alkyl;

R_{21}, R_{22}, and R_{23} are each independently hydrogen or C_1-C_3 linear alkyl; and

d is 3 or 4;

R_1 is a) hydrogen;

b) C_1-C_6alkyl optionally mono- or di-substituted with hydroxy; or

c)



wherein

each R_{24} is independently hydrogen or C_1-C_6alkyl;

each R_{25}, and R_{26} is independently hydrogen or C_1-C_6alkyl;

t is 0 or 1; and

q is 0 or 1;

R_2 is a group selected from (a) – (jj):

(a) 

(b) 

(c) 

(d) 

(e) 

(f)



(g)



(h)



(i)



(j)



(k)



(l)



(m)



(n)



o)



p)



q)



r)



s)



t)



u)



v)



w)



x)



y)



z)



aa)



bb)



cc)



dd)



ee)



ff)



gg)



hh)



ii)



jj)



wherein

each R_{27} and R_{28} is independently selected from:

(1) hydrogen;

(2) C_1-C_6alkyl;

(3) C_1-C_6alkoxy;

(4) $-CO_2$-R_{43} wherein R_{43} is hydrogen or C_1-C_6alkyl;

(5) hydroxy;

(6) $-(CH_2)_a$-OR_{44} wherein a is 1, 2 or 3 and R_{44} is hydrogen or C_1-C_6alkyl;

(7) $-(CO)$-$NR_{45}R_{46}$ wherein R_{45} and R_{46} are each independently hydrogen, C_1-C_2alkyl, or R_{45} and R_{46} taken together form a 5-membered monocyclic ring;

z is 0 or 1;

e is 2, 3, 4, 5, 6 or 7;

h is 0, 1, 2 or 3;

u is 0, 1, 2, 3 or 4;

o is 0 or 1;

l is 0 or 1;

j is 0, 1, 2 or 3;

v is 0, 1, 2, 3 or 4;

w is 1, 2 or 3 as hereinbefore defined;

f is 1, 2, 3 or 4;

t is 0 or 1 as hereinbefore defined;

b is 0, 1 or 2;

q is 0 or 1as hereinbefore defined;

aa is 0 or 2;

X is O, S or NR_{90} wherein R_{90} is hydrogen, C_1-C_6alkyl, or



wherein R_{143} is hydrogen or alkyl;

each M and V is a group independently selected from hydrogen, halogen, C_1-C_6alkyl, C_1-C_6alkoxy, trifluoromethyl, hydroxy, phenyl, phenoxy, $-SO_2NH_2$ or



; or

$-NR_{48}R_{49}$ wherein R_{48} and R_{49} are each independently hydrogen or C_1-C_2alkyl;

each R_{31}, R_{32}, R_{33}, R_{34}, R_{35}, R_{36}, R_{37}, R_{38}, R_{39}, R_{40}, R_{68}, and R_{69} is independently hydrogen or C_1-C_6alkyl;

each R_{29}, R_{30} is independently hydrogen, phenyl or C_1-C_6alkyl;

each R_{83}, R_{84}, R_{86}, R_{87}, R_{88}, R_{89}, R_{92}, R_{93}, R_{98}, R_{99}, R_{94}, R_{95}, R_{100}, R_{101}, R_{103}, R_{104}, R_{105}, R_{106}, R_{108}, R_{109}, R_{110}, R_{111},

R_{113}, R_{114}, R_{115}, R_{116}, R_{117}, R_{118}, R_{119}, R_{120}, R_{122}, R_{123}, R_{124}, R_{125}, R_{127}, R_{128}, R_{130}, R_{131}, R_{133}, R_{134}, R_{135}, R_{136}, R_{137}, R_{138}, R_{139} and R_{140} is independently hydrogen or C_1-C_6alkyl;

each R_{63}, R_{64} and R_{65} is independently hydrogen, halogen, C_1-C_6alkyl or C_1-C_6alkoxy;

each R_{66} is independently hydrogen, hydroxy, C_1-C_6alkyl or C_1-C_6alkoxy;

Q is CH_2, CHOH or C=O;

X_5 is O or S;

each R_{67} is independently hydrogen or C_1-C_6alkyl;

R_{70} is hydrogen, C_1-C_6alkyl, halogen, nitro or a phenyl group optionally mono-substituted with C_1-C_6alkyl, halogen or trifluoromethyl;

R_{81} is hydrogen, C_1-C_6alkyl, or $-CO_2C_1$-C_6alkyl;

R_{91} is hydrogen, halogen, C_1-C_6alkyl or C_1-C_6alkoxy;

R_{96} is hydrogen, C_1-C_6alkyl or



wherein R_{145} and R_{146} are each independently hydrogen or C_1-C_6alkyl and b is 0, 1 or 2 as hereinbefore defined;

R_{97} is hydrogen or C_1-C_6alkyl;

each R_{102} is independently hydrogen, halogen, C_1-C_6alkyl or C_1-C_6alkoxy;

R_{107} is hydrogen or C_1-C_6alkyl;

each R_{121} is independently hydrogen, halogen, C_1-C_6alkyl or C_1-C_6alkoxy;

R_{127} is hydrogen or C_1-C_6alkyl;

R_{126} is C_1-C_6alkyl or benzyl;

R_{129} is hydrogen or C_1-C_6alkyl;

R_{132} is hydrogen, C_1-C_6alkyl, halogen or C_1-C_6alkoxy;

X_3 is O or -NR_{127} wherein R_{127} is hydrogen or C_1-C_6alkyl;

X_4 is O, S or -NR_{143} wherein R_{143} is hydrogen or C_1-C_6alkyl;

R_{141} is hydrogen, C_1-C_6alkyl or amino;

R_{142} is benzyl or phenyl each of which may be optionally substituted with C_1-C_6alkyl, halogen or C_1-C_6alkoxy;

R_{144} is hydrogen or C_1-C_6alkyl;

R_{85} is hydrogen, C_1-C_6alkoxy, C_1-C_6alkyl, -CO_2C_1-C_6alkyl, $C(O)C_1$-C_6alkyl or a group selected from the following:

a) 

b) 

c) 

d) 

e) 

f) 

g) 

h) 

i) 

j) 

k) 

wherein

j is 0, 1, 2 or 3 as hereinbefore defined;

w is 1, 2 or 3 as hereinbefore defined;

m is 0, 1 or 2 as hereinbefore defined;

e is 2, 3, 4, 5, 6 or 7 as hereinbefore defined;

each R_{147}, R_{148}, R_{150}, R_{151}, R_{152}, R_{153}, R_{156}, R_{157}, R_{159}, R_{160} R_{162} and R_{163} is independently hydrogen or C_1-C_6alkyl;

R_{149} is hydrogen, halogen, C_1-C_6alkyl, phenoxy, trifluoromethyl or trifluoromethoxy;

R_{155} is hydrogen, halogen or C_1-C_6alkyl;

R_{158} is hydrogen or C_1-C_6alkyl;

R_{161} is hydrogen or C_1-C_6alkyl;

R_{164} is hydrogen, halogen, C_1-C_6alkyl or trifluoromethyl;

R_{165} is hydrogen, C_1-C_6alkyl or halogen;

X_7 is O or S or -NR_{167} wherein R_{167} is hydrogen or C_1-C_6alkyl;

R_{166} is hydrogen or C_1-C_6alkyl;

or R_1 and R_2 are joined together to form a 5-, 6-, or 7-membered monocyclic saturated ring, and in which the ring is optionally mono- or di-substituted, the substituents independently selected from:

(1) C_1-C_6alkyl;

(2) –CO_2-(C_1-C_6alkyl);

(3) –$NR_{50}R_{51}$ wherein R_{50} and R_{51} are each independently hydrogen, C_1-C_6alkyl, or a phenyl group which is optionally mono- or disubstituted with substituents independently selected from C_1-C_6alkyl, halogen or trifluoromethyl;

(4) -C(O)phenyl wherein the phenyl group is optionally mono- or disubstituted with substituents independently selected from C_1-C_6alkyl, halogen or trifluoromethyl;

(5) –$(CH_2)_mOR_{52}$ wherein R_{52} is hydrogen or C_1-C_2alkyl or a phenyl group which is optionally mono- or disubstituted with substituents independently selected from C_1-C_6alkyl, halogen or trifluoromethyl, and m is 0, 1 or 2 as hereinbefore defined;

(6) –NR_{54}-COR_{53} wherein R_{54} is hydrogen or C_1-C_6alkyl and R_{53} is hydrogen or C_1-C_2alkyl ;

(7) =O;

(8) –CN;

(9)



(10)



(11)



(12)



(13)



(14)



(15)



(16)



(17)



wherein

b is 0, 1 or 2 as hereinbefore defined;

w is 1, 2 or 3 as hereinbefore defined;

t is 0 or 1 as hereinbefore defined;

i is 0, 1 or 2;

v is 0, 1, 2, 3 or 4 as hereinbefore defined;

k is 0 or 1 as hereinbefore defined;

c are 0, 1 or 2;

R_{167} is hydrogen or C_1-C_6alkyl;

each R_{55}, R_{56}, R_{58}, R_{59}, R_{169} and R_{170} is independently hydrogen or C_1-C_6alkyl;

each R_{57} is independently hydrogen, halogen or C_1-C_6alkyl;

each R_{60} is independently hydrogen, halogen or C_1-C_6alkyl;

R_{61} and R_{62} are each independently hydrogen or C_1-C_6alkyl;

R_{168} is hydrogen, thienyl or furanyl;

R_{171} is hydrogen, C_1-C_6alkyl, halogen, trifluoromethyl or trifluoromethoxy;

or R_1 and R_2 are joined together to form a group of formula X;



(X)

or R_1 and R_2 are joined together to form the group of formula (Y)



(Y)

or R_1 and R_2 are joined together to form any of the following groups:

(a)



(b)



(c)



(d)



(e)



wherein

g is 1 or 2 as hereinbefore defined;

p is 0, 1 or 2 as hereinbefore defined;

R_{172} is hydrogen, C_1-C_6alkyl or C_1-C_6alkoxy;

R_{173} is hydrogen, C_1-C_6alkyl or phenyl optionally mono- or disubstituted with C_1-C_6alkyl or halogen; and

R_{82} is a substituent selected from the following groups:

(a) C_1-C_6alkyl optionally substituted with hydroxy;

(b) C_1-C_6alkenyl;

(c) C_1-C_6alkoxy;

(d) -$(CH_2)OC_1$-C_6alkyl;

(e)



wherein X_8 is -$(CR_{175}R_{176})_h$- or —$(CR_{177}=CR_{188})$—

wherein each R_{174} is independently hydrogen, C_1-C_6alkyl, halogen, trifluoromethyl, C_1-C_6alkoxy or benzyloxy;
h is 0, 1, 2 or 3 as hereinbefore defined;
each R_{175}, R_{176}, R_{177} and R_{178} is independently hydrogen or C_1-C_6alkyl; and
j is 0, 1, 2 or 3 as hereinbefore defined;

(f)



wherein X_9 is $-(CR_{180}R_{181})_j-$ or



or



wherein
aa is 0 or 2 as hereinbefore defined;
R_{179} is hydrogen, C_1-C_6alkyl, halogen, trifluoromethyl,
C_1-C_6alkoxy, benzyloxy or phenyl;
each R_{180}, R_{181}, R_{182}, R_{183}, R_{184}, R_{185}, R_{186} and R_{187} is independently hydrogen or C_1-C_6alkyl;
j is 0, 1, 2, or 3 as hereinbefore defined;

(g)



wherein w is 1, 2 or 3 as hereinbefore defined;

each R_{188} and R_{189} is independently hydrogen or C_1-C_6alkyl;

(h)



wherein

i is 0, 1 or 2 as hereinbefore defined;

each R_{190} is independently hydrogen, alkyl or halogen;

b is 0, 1, or 2 as hereinbefore defined;

each R_{191} and R_{192} is independently hydrogen or C_1-C_6alkyl;

(i)



wherein

a is 1, 2 or 3 as hereinbefore defined;

each R_{193} and R_{194} is independently hydrogen or C_1-C_6alkyl;

R_{195} is hydrogen, halogen or C_1-C_6alkyl;

(j)



wherein

e is 2, 3, 4, 5 or 6 as hereinbefore defined;

b is 0, 1 or 2 as hereinbefore defined;

each R_{196} and R_{197} is independently hydrogen or C_1-C_6alkyl;
each R_{198} and R_{199} is independently hydrogen or C_1-C_6alkyl;

(k)



(l)



wherein

each R_{200} and R_{201} is independently hydrogen or C_1-C_6alkyl;
w is 1, 2 or 3 as hereinbefore defined;

(m)



wherein

each R_{202}, R_{203}, R_{204} and R_{205} is independently hydrogen or C_1-C_6alkyl; and
w is 1, 2 or 3 is as hereinbefore defined;

(n)



wherein

C_1-C_6alkyl is optionally substituted with hydroxy;
each R_{206} and R_{207} is independently hydrogen or C_1-C_6alkyl; and
w is 1, 2 or 3 as hereinbefore defined;

(o)



wherein
each R_{208}, R_{209}, R_{210} and R_{211} is
independently hydrogen or C_1-C_6alkyl;
w is 1, 2 or 3 as hereinbefore defined;

(p)



with the proviso that when n is 1; and y is 0; and R_3 is hydrogen or C_1-C_6alkyl; and



is group (a);

and R is group:

(a) wherein R_4 is hydrogen, halogen or C_1-C_6alkyl, and R_1 is hydrogen or unsubstituted C_1-C_6alkyl,
then R_2 cannot be a group of the following formula:
(a) wherein z is 0,
(b) wherein u is 0 and M is hydrogen, halogen, C_1-C_6alkyl, or trifluoromethyl,
(c) wherein o is 0,
(d) wherein l is 0,
(e) wherein j is 0,
(g) wherein v is 0, or
(i);

and also when R is the group of formula (a), R_1 and R_2 cannot be joined together to form the group of formula Y or a 5-, 6-, or 7-membered monocyclic ring wherein said ring is unsubstituted or mono- or di-substituted with C_1-C_6alkyl;

(b) and R_1 is hydrogen or unsubstituted C_1-C_6alkyl, then R_2 cannot be a group of the following formula:

(a),

(b),

(c) wherein o is 0,

(d) wherein l is 0,

(i),

(k),

(l), or

(m) wherein Q is CH_2;

and also when R is the group of formula (b), R_1 and R_2 cannot be joined together to form a group of formula X or a group of formula Y or a 5-, 6-, or 7-membered monocyclic ring

wherein said ring is unsubstituted or mono- or di-substituted with C_1-C_6alkyl or



;

(c) and R_1 is hydrogen or unsubstituted C_1-C_6alkyl, then R_2 cannot be a group of the following formula:

(c) wherein o is 0,

(d) wherein l is 0, or

(i);

(d) and R_1 is hydrogen or unsubstituted C_1-C_6alkyl, then R_2 cannot be a group of the following formula:

(a),

(b) wherein u is 1,

(c) wherein o is 0,

(d),

(i),

(k),

(l), or

(m) wherein Q is CH_2;

and also when R is the group of formula (d), R_1 and R_2 cannot be joined together to form a group of formula X or a group of formula Y or a 5-, 6-, or 7-membered monocyclic ring

wherein said ring is unsubstituted or mono- or di-substituted with C_1-C_6alkyl or



;

(e) and R_1 is hydrogen or unsubstituted C_1-C_6alkyl, then R_2 cannot be a group of the following formula:

(a),

(b),

(c) wherein o is 0,

(d),

(i),

(k),

(l), or

(m) wherein Q is CH_2;

and also when R is the group of formula (e), R_1 and R_2 cannot be joined together to form a group of formula X or a group of formula Y or a 5-, 6-, or 7-membered monocyclic ring

wherein said ring is unsubstituted or mono- or di-substituted with C_1-C_6alkyl or



;

(f) and R_1 is hydrogen or unsubstituted C_1-C_6alkyl, then R_2 cannot be a group of the following formula:

(a),

(b),

(c) wherein o is 0,

(d),

(i),

(k),

(l), or

(m) wherein Q is CH_2;

and also when R is the group of formula (f), R_1 and R_2 cannot be joined together to form a group of formula X or a group of formula Y or a 5-, 6-, or 7-membered monocyclic ring

wherein said ring is unsubstituted or mono- or di-substituted with C_1-C_6alkyl or



;

(g) and R_1 is hydrogen or unsubstituted C_1-C_6alkyl, then R_2 cannot be a group of the following formula:

(a),

(b) wherein u is1,

(c) wherein o is 0,

(d),

(i),

(k),
(l), or
(m) wherein Q is CH_2;

and also when R is the group of formula (g), R_1 and R_2 cannot be joined together to form a group of formula X or a group of formula Y or a 5-, 6-, or 7-membered monocyclic ring

wherein said ring is unsubstituted or mono- or di-substituted with C_1-C_6alkyl or



;

(h) and R_1 is hydrogen or unsubstituted C_1-C_6alkyl, then R_2 cannot be a group of the following formula:
(a),
(b),
(c) wherein o is 0,
(d),
(i),
(k),
(l), or
(m) wherein Q is CH_2;

and also when R is the group of formula (h), R_1 and R_2 cannot be joined together to form a group of formula X or a group of formula Y or a 5-, 6-, or 7-membered monocyclic ring

wherein said ring is unsubstituted or mono- or di-substituted with C_1-C_6alkyl or



; or

(j), then R_1 and R_2 cannot be joined together to form a group of formula Y or a 5-, 6-, or 7-membered monocyclic ring

wherein said ring is unsubstituted or mono- or di-substituted with C_1-C_6alkyl.

2. The compound of claim 1 wherein R is group (a).

3. The compound of claim 2 wherein R_4 is halogen or CF_3.

4. The compound of claim 3 wherein R_2 is group (a).

5. The compound of claim 4 wherein z is 0 or 1;

e is 5 and each R_{27} and R_{28} is independently selected from hydrogen or C_1-C_6alkyl.

6. The compound of claim 3 wherein R_2 is group (b).

7. The compound of claim 6 wherein M is hydrogen, C_1-C_6alkoxy or C_1-C_6alkyl and u is 0 or 1.

8. The compound of claim 3 wherein R_2 is group (n).

9. The compound of claim 8 wherein R_{70} is hydrogen and f is 3.

10. The compound of claim 1 wherein R is group (k).

11. The compound of claim 10 wherein R_{12} is hydrogen, C_1-C_6alkyl, or -CH_2OC_1-C_6alkyl.

12. The compound of claim 11 wherein wherein R_2 is group (a).

13. The compound of claim 12 wherein z is 0 or 1;

e is 5 and each R_{27} and R_{28} is independently selected from hydrogen or C1-C6alkyl.

14. The compound of claim 11 wherein R_2 is group (b).

15. The compound of claim 14 wherein M is hydrogen, C_1-C_6alkoxy or C_1-C_6alkyl and u is 0 or 1.

16. The compound of claim 11 wherein R_2 is group (n).

17. The compound of claim 17 wherein R_{70} is hydrogen and f is 3.

18. The compound of claim 1 which is 2-[4-(6-trifluoromethyl-benzo[*b*]thiophen-3-yl)-piperazin-1-ylmethyl]-*trans*-cyclopropanecarboxylic acid (*trans*-4-ethyl-cyclohexyl)-amide.

19 The compound of claim 1 which is 2-[4-(2,4-dimethyl-phenyl)-piperazin-1-ylmethyl]-(2R, 3R)-cyclopropanecarboxylic acid (*trans*-4-ethyl-cyclohexyl)-amide.

20. The compound of claim 1 which is 2-[4-(chloro-trifluoromethyl-pyridin-2-yl)-piperazin-1-ylmethyl]-(2R, 3R)-cyclopropanecarboxylic acid (*trans*-4-ethyl-cyclohexyl)-amide.

21. The compound of claim 1 which is 2-[4-(2,5-dimethyl-phenyl)-piperazin-1-ylmethyl]-(2R, 3R)-cyclopropanecarboxylic acid (*trans*-4-ethyl-cyclohexyl)-amide.

22. The compound of claim 1 which is 2-[4-(6-trifluoromethyl-benzo[b]thiophen-3-yl)-piperazin-1-ylmethyl]-(2R, 3R)-cyclopropanecarboxylic acid (trans-4-methyl-cyclohexyl)-amide.

23. The compound of claim 1 which is 2-(4-thieno[2,3-*d*]isoxazol-3-yl-piperidin-1-ylmethyl)-(2R, 3R)-cyclopropanecarboxylic acid (*trans*-4-methyl-cyclohexyl)-amide.

24. The compound of claim 1 which is 2-[4-*o*-tolyl-piperazin-1-ylmethyl]-(2R, 3R)-cyclopropanecarboxylic acid (*trans*-4-ethyl-cyclohexyl)-amide.

25. The compound of claim 1 which is 4-[4-(6-fluoro-benzo[*b*]thiophen-3-yl)-piperazin-1-yl]-*N*-(*trans*-4-methyl-cyclohexyl)-butyramide.

26. The compound of claim 1 which is 2-(4-thieno[2,3-*d*]isoxazol-3-yl-piperidin-1-ylmethyl)-(2R, 3R)-cyclopropanecarboxylic acid (3-imidazol-1-yl-propyl)-amide.

27. The compound of claim 1 which is 2-(4-thieno[2,3-*d*]isoxazol-3-yl-piperazin-1-ylmethyl)-(2R, 3R)-cyclopropanecarboxylic acid (*trans*-4-methyl-cyclohexyl)-amide.

28. The compound of claim 1 which is 2R-[4-(1-Methyl-1H-thieno[3,2-c]pyrazol-3-yl)-piperazin-1-ylmethyl]-cyclopropane-1R-carboxylic trans-(4-methyl-cyclohexyl)-amide.

29. The compound of claim 1 which is 2R-[4-(5-Trifluoromethyl-benzo[d]isoxazol-3-yl)-piperidin-1-ylmethyl]- cyclopropane-1R-carboxylic acid trans-(4-methyl-cyclohexyl)-amide.

30. The compound of claim 1 which is (3S-Imidazol-1-ylmethyl-piperidin-1-yl)-{2R-[4-(7-methoxy-benzo[d]isoxazol-3-yl)-piperidin-1-ylmethyl]-1R-cyclopropyl}-methanone.

31. The compound of claim 1 which is 2R-[4-(1-Methyl-7-trifluoromethyl-1H-indazol-3-yl)-piperidin-1-ylmethyl]-1R-cycloproanecarboxylic acid (3-imidazol-1-yl-propyl)-amide.

32. The compound of claim 1 which is (3S-Imidazol-1-ylmethyl-piperidin-1-yl)-{2R-[4-(7-trifluoromethyl-benzo[d]isoxazol-3-yl)-piperidin-1-ylmethyl]-1R-cyclopropyl}-methanone.

33. The compound of claim 1 which is 2R-[4-(7-Trifluoromethyl-benzo[b]thiophen-3-yl)-piperidin-1-ylmethyl]-1R-cyclopropanecarboxylic acid (trans-4-methyl-cyclohexyl)-amide.

34. The compound of claim 1 which is (3S-Imidazol-1-ylmethyl-piperidin-1-yl)-{2R-[4-(1-methyl-6-trifluoromethyl-1H-indazol-3-yl)-piperidin-1-ylmethyl]-1R-cyclopropyl}-methanone.

35. The compound of claim 1 which is 2R-[4-(6-Trifluoromethyl-benzo[d]isoxazol-3-yl)-piperidin-1-ylmethyl]-1R-cycloproanecarboxylic acid (3-imidazol-1-yl-propyl)-amide.

36. The compound of claim 1 which is (3S-Imidazol-1-ylmethyl-piperidin-1-yl)-{2R-[4-(6-trifluoromethyl-benzo[b]thiophen-3-yl)-piperidin-1-ylmethyl]-1R-cyclopropyl}-methanone.

37. The compound of claim 1 which is 2R-[4-(6-Fluoro-7-methoxy-benzo[d]isoxazol-3-yl)-piperidin-1-ylmethyl]-1R-cyclopranecarboxylic acid (trans-4-methyl-cyclohexyl)-amide.

38. The compound of claim 1 which is 2R-[4-(1-Methyl-1H-thieno[3,2-c]pyrazol-3-yl)-piperidin-1-ylmethyl]-1R-cycloproanecarboxylic acid (3-imidazol-1-yl-propyl)-amide.

39. The compound of claim 1 which is 2R-{4-[1-(2,2,2-Trifluoro-ethyl)-1H-thieno[3,2-c]pyrazol-3-yl)-piperidin-1-ylmethyl]-1R-cycloproanecarboxylic acid (3-imidazol-1-yl-propyl)-amide.

40. The compound of claim 1 which is 2R-(4-Thieno[2,3-d]isoxazol-3-yl-piperazin-1-ylmethyl)-1R-cyclopropanecarboxylic acid (3-imidazol-1-yl-propyl)-amide

41. The compound of claim 1 which is 2R-(4-Benzo[b]thiophen-2-yl-piperidin-1-ylmethyl)-1R-cyclopranecarboxylic acid (trans-4-methyl-cyclohexyl)-amide.

42. The compound of claim 1 which is 2R-[4-(5,6-Dihydro-4H-imidazo[4,5,1-ij]quinolin-2-yl)-piperazin-1-ylmethyl]-1R-cyclopranecarboxylic acid (trans-4-methyl-cyclohexyl)-amide.

43. The compound of claim 1 which is 2R-(4-Thieno[2,3-b]pyridin-3-yl-piperazin-1-ylmethyl)-1R-cyclopropanecarboxylic acid (3-imidazol-1-yl-propyl)-amide

44. The compound of claim 1 which is 1-{2-[4-(6-Trifluoromethyl-benzo[b]thiophen-3-yl)-piperazin-1-yl]-ethyl}-cyclopropanecarboxylic acid (3-imidazol-1-yl-propyl)-amide.

45. A method of modulating the activity of dopamine D_3 receptors, said method comprising: contacting cell-associated dopamine D_3 receptors with a concentration of a compound of formula IB, or a physiologically acceptable salt thereof, sufficient to modulate the activity of said dopamine D_3 receptor wherein said compound of formula IB has the structure:



IB

wherein

A is CH or N;

n is 1 or 2;

when n is 1, y is 0 or 2;

when n is 2, y is 0;

g is 1 or 2;

each R_3 is independently hydrogen, C_1-C_6alkyl, or



wherein w is 1, 2, or 3;

R is selected from the group consisting of (a) – (w):

a) 

b) 

c) 

d) 

e) 

f) 

g) 

h) 

i) 

j) 

k) 

l) 

m) $-CO_2R_{16}$

n) 

o)



p)



q)



r)



s)



t)



u)



v)



w)



wherein

each R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11}, R_{12} and R_{18} is independently hydrogen, C_1-C_6alkyl, halogen, trifluoromethyl, -CO_2C_1-C_6alkyl or -CH_2OC_1-C_6alkyl;

each R_{71}, R_{72}, R_{74} and R_{80} is independently hydrogen, C_1-C_6alkyl, C_1-C_6alkoxy, halogen, trifluoromethyl, -CO_2C_1-C_6alkyl or -CH_2OC_1-C_6alkyl;

R_{73} is hydrogen, alkyl, pyridyl, benzyl, $-CH_2CF_3$, $-CO_2C_1$-C_6alkyl, phenyl optionally substituted with halogen, trifluoromethyl, trifluoromethoxy or

R_{73} is



wherein w is 1, 2 or 3 as hereinbefore defined;

each R_{75} is hydrogen, halogen, C_1-C_6alkyl or C_1-C_6alkoxy;

each R_{76} is hydrogen, halogen, -CN or C_1-C_6alkyl;

each R_{77} is hydrogen, halogen, C_1-C_6alkyl or C_1-C_6alkoxy;

each R_{78} hydrogen, halogen, C_1-C_6alkyl or C_1-C_6alkoxy;

each R_{79} hydrogen, halogen, C_1-C_6alkyl or C_1-C_6alkoxy;

p, s and x are 0, 1, or 2;

each R_{13} is independently hydrogen, C_1-C_6alkyl, halogen, benzyl, trifluoromethyl, C_1-C_6alkoxy, nitro, -CN, or $-COC_1$-C_6alkyl;

R_{16} is C_1-C_6alkyl;

each R_{14} and R_{15} is independently hydrogen or C_1-C_6alkyl;

R_{17} is hydrogen, C_1-C_6alkyl, Ar, -COAr, -CONHAr or $-SO_2$-Ar wherein Ar is a phenyl group which is optionally mono- or di-substituted with substituents independently selected from C_1-C_6alkyl, halogen, trifluoromethyl, C_1-C_6alkoxy, nitro, CN and COC_1-C_6alkyl; and

m is 0, 1, or 2;



represents a group selected from (a) - (f):

a) 

b)



(c)



(d)



(e)



(f)



wherein

each R_{19} and R_{20} is independently hydrogen, hydroxy or C_1-C_6alkyl;

R_{21}, R_{22}, and R_{23} are each independently hydrogen or C_1-C_3 linear alkyl; and

d is 3 or 4;

R_1 is a) hydrogen;

b) C_1-C_6alkyl optionally mono- or di-substituted with hydroxy; or

c)



wherein

each R_{24} is independently hydrogen or C_1-C_6alkyl;

each R_{25}, and R_{26} is independently hydrogen or C_1-C_6alkyl;

t is 0 or 1; and

q is 0 or 1;

R_2 is a group selected from (a) – (jj):

(a) 

(b) 

(c) 

(d) 

(e) 

(f)



(g)



(h)



(i)



(j)



(k)



(l)



(m)



(n)



o)



p)



q)



r)



s)



t)



u)



v)



w)



x)



y)



z)



aa)



bb)



cc)



dd)



ee)



ff)



gg)



hh)



ii)



jj)



wherein

each R_{27} and R_{28} is independently selected from:

(8) hydrogen;

(9) C_1-C_6alkyl;

(10) C_1-C_6alkoxy;

(11) $-CO_2$-R_{43} wherein R_{43} is hydrogen or C_1-C_6alkyl;

(12) hydroxy;

(13) $-(CH_2)_a$-OR_{44} wherein a is 1, 2 or 3 and R_{44} is hydrogen or C_1-C_6alkyl;

(14) $-(CO)$-$NR_{45}R_{46}$ wherein R_{45} and R_{46} are each independently hydrogen, C_1-C_2alkyl, or R_{45} and R_{46} taken together form a 5-membered monocyclic ring;

z is 0 or 1;

e is 2, 3, 4, 5, 6 or 7;

h is 0, 1, 2 or 3;

u is 0, 1, 2, 3 or 4;

o is 0 or 1;

l is 0 or 1;

j is 0, 1, 2 or 3;

v is 0, 1, 2, 3 or 4;

w is 1, 2 or 3 as hereinbefore defined;

f is 1, 2, 3 or 4;

t is 0 or 1 as hereinbefore defined;

b is 0, 1 or 2;

q is 0 or 1as hereinbefore defined;

aa is 0 or 2;

X is O, S or NR_{90} wherein R_{90} is hydrogen, C_1-C_6alkyl, or



wherein R_{143} is hydrogen or alkyl;

each M and V is a group independently selected from hydrogen, halogen, C_1-C_6alkyl, C_1-C_6alkoxy, trifluoromethyl, hydroxy, phenyl, phenoxy, $-SO_2NH_2$ or


; or

$-NR_{48}R_{49}$ wherein R_{48} and R_{49} are each independently hydrogen or C_1-C_2alkyl;

each R_{31}, R_{32}, R_{33}, R_{34}, R_{35}, R_{36}, R_{37}, R_{38}, R_{39}, R_{40}, R_{68}, and R_{69} is independently hydrogen or C_1-C_6alkyl;

each R_{29}, R_{30} is independently hydrogen, phenyl or C_1-C_6alkyl;

each R_{83}, R_{84}, R_{86}, R_{87}, R_{88}, R_{89}, R_{92}, R_{93}, R_{98}, R_{99}, R_{94}, R_{95}, R_{100}, R_{101}, R_{103}, R_{104}, R_{105}, R_{106}, R_{108}, R_{109}, R_{110}, R_{111},

R_{113}, R_{114}, R_{115}, R_{116}, R_{117}, R_{118}, R_{119}, R_{120}, R_{122}, R_{123}, R_{124}, R_{125}, R_{127}, R_{128}, R_{130}, R_{131}, R_{133}, R_{134}, R_{135}, R_{136}, R_{137}, R_{138}, R_{139} and R_{140} is independently hydrogen or C_1-C_6alkyl;

each R_{63}, R_{64} and R_{65} is independently hydrogen, halogen, C_1-C_6alkyl or C_1-C_6alkoxy;

each R_{66} is independently hydrogen, hydroxy, C_1-C_6alkyl or C_1-C_6alkoxy;

Q is CH_2, CHOH or C=O;

X_5 is O or S;

each R_{67} is independently hydrogen or C_1-C_6alkyl;

R_{70} is hydrogen, C_1-C_6alkyl, halogen, nitro or a phenyl group optionally mono-substituted with C_1-C_6alkyl, halogen or trifluoromethyl;

R_{81} is hydrogen, C_1-C_6alkyl, or $-CO_2C_1$-C_6alkyl;

R_{91} is hydrogen, halogen, C_1-C_6alkyl or C_1-C_6alkoxy;

R_{96} is hydrogen, C_1-C_6alkyl or



wherein R_{145} and R_{146} are each independently hydrogen or C_1-C_6alkyl and b is 0, 1 or 2 as hereinbefore defined;

R_{97} is hydrogen or C_1-C_6alkyl;

each R_{102} is independently hydrogen, halogen, C_1-C_6alkyl or C_1-C_6alkoxy;

R_{107} is hydrogen or C_1-C_6alkyl;

each R_{121} is independently hydrogen, halogen, C_1-C_6alkyl or C_1-C_6alkoxy;

R_{127} is hydrogen or C_1-C_6alkyl;

R_{126} is C_1-C_6alkyl or benzyl;

R_{129} is hydrogen or C_1-C_6alkyl;

R_{132} is hydrogen, C_1-C_6alkyl, halogen or C_1-C_6alkoxy;
X_3 is O or -NR_{127} wherein R_{127} is hydrogen or C_1-C_6alkyl;
X_4 is O, S or -NR_{143} wherein R_{143} is hydrogen or C_1-C_6alkyl;
R_{141} is hydrogen, C_1-C_6alkyl or amino;
R_{142} is benzyl or phenyl each of which may be optionally substituted with C_1-C_6alkyl, halogen or C_1-C_6alkoxy;
R_{144} is hydrogen or C_1-C_6alkyl;
R_{85} is hydrogen, C_1-C_6alkoxy, C_1-C_6alkyl, -CO_2C_1-C_6alkyl, $C(O)C_1$-C_6alkyl or a group selected from the following:

a) 

b) 

c) 

d) 

e) 

f) 

g) 

h) 

i) 

j) 

k) 

wherein

j is 0, 1, 2 or 3 as hereinbefore defined;

w is 1, 2 or 3 as hereinbefore defined;

m is 0, 1 or 2 as hereinbefore defined;

e is 2, 3, 4, 5, 6 or 7 as hereinbefore defined;

each R_{147}, R_{148}, R_{150}, R_{151}, R_{152}, R_{153}, R_{156}, R_{157}, R_{159}, R_{160} R_{162} and R_{163} is independently hydrogen or C_1-C_6alkyl;

R_{149} is hydrogen, halogen, C_1-C_6alkyl, phenoxy, trifluoromethyl or trifluoromethoxy;

R_{155} is hydrogen, halogen or C_1-C_6alkyl;

R_{158} is hydrogen or C_1-C_6alkyl;

R_{161} is hydrogen or C_1-C_6alkyl;

R_{164} is hydrogen, halogen, C_1-C_6alkyl or trifluoromethyl;

R_{165} is hydrogen, C_1-C_6alkyl or halogen;

X_7 is O or S or -NR_{167} wherein R_{167} is hydrogen or C_1-C_6alkyl;

R_{166} is hydrogen or C_1-C_6alkyl;

or R_1 and R_2 are joined together to form a 5-, 6-, or 7-membered monocyclic saturated ring, and in which the ring is optionally mono- or di-substituted, the substituents independently selected from:

(1) C_1-C_6alkyl;

(9) –CO_2-(C_1-C_6alkyl);

(10) –$NR_{50}R_{51}$ wherein R_{50} and R_{51} are each independently hydrogen, C_1-C_6alkyl, or a phenyl group which is optionally mono- or disubstituted with substituents independently selected from C_1-C_6alkyl, halogen or trifluoromethyl;

(11) -C(O)phenyl wherein the phenyl group is optionally mono- or disubstituted with substituents independently selected from C_1-C_6alkyl, halogen or trifluoromethyl;

(12) –$(CH_2)_mOR_{52}$ wherein R_{52} is hydrogen or C_1-C_2alkyl or a phenyl group which is optionally mono- or disubstituted with substituents independently selected from C_1-C_6alkyl, halogen or trifluoromethyl, and m is 0, 1 or 2 as hereinbefore defined;

(13) –NR_{54}-COR_{53} wherein R_{54} is hydrogen or C_1-C_6alkyl and R_{53} is hydrogen or C_1-C_2alkyl ;

(14) =O;

(15) –CN;

(9)



(10)



(11)



(12)



(13)



(14)



(15)



(16)



(17)



wherein

b is 0, 1 or 2 as hereinbefore defined;

w is 1, 2 or 3 as hereinbefore defined;

t is 0 or 1 as hereinbefore defined;

i is 0, 1 or 2;

v is 0, 1, 2, 3 or 4 as hereinbefore defined;

k is 0 or 1 as hereinbefore defined;

c are 0, 1 or 2;

R_{167} is hydrogen or C_1-C_6alkyl;

each R_{55}, R_{56}, R_{58}, R_{59}, R_{169} and R_{170} is independently hydrogen or C_1-C_6alkyl;

each R_{57} is independently hydrogen, halogen or C_1-C_6alkyl;

each R_{60} is independently hydrogen, halogen or

C_1-C_6alkyl;

R_{61} and R_{62} are each independently hydrogen or C_1-C_6alkyl;

R_{168} is hydrogen, thienyl or furanyl;

R_{171} is hydrogen, C_1-C_6alkyl, halogen, trifluoromethyl or trifluoromethoxy;

or R_1 and R_2 are joined together to form a group of formula X;



(X)

or R_1 and R_2 are joined together to form the group of formula (Y)



(Y)

or R_1 and R_2 are joined together to form any of the following groups:

(a) 

(b) 

(c) 

(d) 

(e) 

wherein

g is 1 or 2 as hereinbefore defined;

p is 0, 1 or 2 as hereinbefore defined;

R_{172} is hydrogen, C_1-C_6alkyl or C_1-C_6alkoxy;

R_{173} is hydrogen, C_1-C_6alkyl or phenyl optionally mono- or disubstituted with C_1-C_6alkyl or halogen; and

R_{82} is a substituent selected from the following groups:

(a) C_1-C_6alkyl optionally substituted with hydroxy;

(b) C_1-C_6alkenyl;

(c) C_1-C_6alkoxy;

(d) -$(CH_2)OC_1$-C_6alkyl;

(e)



wherein X_8 is -$(CR_{175}R_{176})_h$- or —$(CR_{177}=CR_{188})$—

wherein each R_{174} is independently hydrogen, C_1-C_6alkyl, halogen, trifluoromethyl, C_1-C_6alkoxy or benzyloxy;
h is 0, 1, 2 or 3 as hereinbefore defined;
each R_{175}, R_{176}, R_{177} and R_{178} is independently hydrogen or C_1-C_6alkyl; and
j is 0, 1, 2 or 3 as hereinbefore defined;

(f)



wherein X_9 is $-(CR_{180}R_{181})_j-$ or



or



wherein
aa is 0 or 2 as hereinbefore defined;
R_{179} is hydrogen, C_1-C_6alkyl, halogen, trifluoromethyl,
C_1-C_6alkoxy, benzyloxy or phenyl;
each R_{180}, R_{181}, R_{182}, R_{183}, R_{184}, R_{185}, R_{186} and R_{187} is independently hydrogen or C_1-C_6alkyl;
j is 0, 1, 2, or 3 as hereinbefore defined;

(g)



wherein w is 1, 2 or 3 as hereinbefore defined;

each R_{188} and R_{189} is independently hydrogen or C_1-C_6alkyl;

(h)



wherein

i is 0, 1 or 2 as hereinbefore defined;

each R_{190} is independently hydrogen, alkyl or halogen;

b is 0, 1, or 2 as hereinbefore defined;

each R_{191} and R_{192} is independently hydrogen or C_1-C_6alkyl;

(i)



wherein

a is 1, 2 or 3 as hereinbefore defined;

each R_{193} and R_{194} is independently hydrogen or C_1-C_6alkyl;

R_{195} is hydrogen, halogen or C_1-C_6alkyl;

(j)



wherein

e is 2, 3, 4, 5 or 6 as hereinbefore defined;

b is 0, 1 or 2 as hereinbefore defined;

each R_{196} and R_{197} is independently hydrogen or C_1-C_6alkyl;
each R_{198} and R_{199} is independently hydrogen or C_1-C_6alkyl;

(k)



(l)



wherein

each R_{200} and R_{201} is independently hydrogen or C_1-C_6alkyl;
w is 1, 2 or 3 as hereinbefore defined;

(m)



wherein

each R_{202}, R_{203}, R_{204} and R_{205} is independently hydrogen or C_1-C_6alkyl; and
w is 1, 2 or 3 is as hereinbefore defined;

(n)



wherein

C_1-C_6alkyl is optionally substituted with hydroxy;
each R_{206} and R_{207} is independently hydrogen or C_1-C_6alkyl; and
w is 1, 2 or 3 as hereinbefore defined;

(o)



wherein

each R_{208}, R_{209}, R_{210} and R_{211} is independently hydrogen or C_1-C_6alkyl;

w is 1, 2 or 3 as hereinbefore defined;

(p)



46. A method of treating conditions or disorders of the central nervous system comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula IA, or a pharmaceutically acceptable salt thereof wherein said compound of formula IA has the structure:



IA

wherein

A is CH or N;

n is 1 or 2;

when n is 1, y is 0 or 2;

when n is 2, y is 0;

g is 1 or 2;

each R_3 is independently hydrogen, C_1-C_6alkyl, or



wherein w is 1, 2, or 3;

R is selected from the group consisting of (a) – (w):

a) 

b) 

c) 

d) 

e) 

f) 

g) 

h) 

i) 

j) 

k) 

l) 

m) $-CO_2R_{16}$

n) 

o)



p)



q)



r)



s)



t)



u)



v)



w)



wherein

each R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11}, R_{12} and R_{18} is independently hydrogen, C_1-C_6alkyl, halogen, trifluoromethyl, -CO_2C_1-C_6alkyl or -CH_2OC_1-C_6alkyl;

each R_{71}, R_{72}, R_{74} and R_{80} is independently hydrogen, C_1-C_6alkyl, C_1-C_6alkoxy, halogen, trifluoromethyl, -CO_2C_1-C_6alkyl or -CH_2OC_1-C_6alkyl;

R_{73} is hydrogen, alkyl, pyridyl, benzyl, -CH_2CF_3, -CO_2C_1-C_6alkyl, phenyl optionally substituted with halogen, trifluoromethyl, trifluoromethoxy or

R_{73} is



wherein w is 1, 2 or 3 as hereinbefore defined;

each R_{75} is hydrogen, halogen, C_1-C_6alkyl or C_1-C_6alkoxy;

each R_{76} is hydrogen, halogen, -CN or C_1-C_6alkyl;

each R_{77} is hydrogen, halogen, C_1-C_6alkyl or C_1-C_6alkoxy;

each R_{78} hydrogen, halogen, C_1-C_6alkyl or C_1-C_6alkoxy;

each R_{79} hydrogen, halogen, C_1-C_6alkyl or C_1-C_6alkoxy;

p, s and x are 0, 1, or 2;

each R_{13} is independently hydrogen, C_1-C_6alkyl, halogen, benzyl, trifluoromethyl, C_1-C_6alkoxy, nitro, -CN, or -COC_1-C_6alkyl;

R_{16} is C_1-C_6alkyl;

each R_{14} and R_{15} is independently hydrogen or C_1-C_6alkyl;

R_{17} is hydrogen, C_1-C_6alkyl, Ar, -COAr, -CONHAr or -SO_2-Ar wherein Ar is a phenyl group which is optionally mono- or di-substituted with substituents independently selected from C_1-C_6alkyl, halogen, trifluoromethyl, C_1-C_6alkoxy, nitro, CN and COC_1-C_6alkyl; and

m is 0, 1, or 2;



represents a group selected from (a) - (f):

a) 

b)



(c)



(d)



(e)



(f)



wherein

each R_{19} and R_{20} is independently hydrogen, hydroxy or C_1-C_6alkyl;

R_{21}, R_{22}, and R_{23} are each independently hydrogen or C_1-C_3 linear alkyl; and

d is 3 or 4;

R_1 is a) hydrogen;

b) C_1-C_6alkyl optionally mono- or di-substituted with hydroxy; or

c)



wherein

each R_{24} is independently hydrogen or C_1-C_6alkyl;

each R_{25}, and R_{26} is independently hydrogen or C_1-C_6alkyl;

t is 0 or 1; and

q is 0 or 1;

R_2 is a group selected from (a) – (jj):

(a) 

(b) 

(c) 

(d) 

(e) 

(f)



(g)



(h)



(i)



(j)



(k)



(l)



(m)



(n)



o)



p)



q)



r)



s)



t)



u)



v)



w)



x)



y)



z)



aa)



bb)



cc)



dd)



ee)



ff)



gg)



hh)



ii)



jj)



wherein

each R_{27} and R_{28} is independently selected from:

(1) hydrogen;

(2) C_1-C_6alkyl;

(3) C_1-C_6alkoxy;

(4) $-CO_2$-R_{43} wherein R_{43} is hydrogen or C_1-C_6alkyl;

(5) hydroxy;

(6) $-(CH_2)_a$-OR_{44} wherein a is 1, 2 or 3 and R_{44} is hydrogen or C_1-C_6alkyl;

(7) $-(CO)$-$NR_{45}R_{46}$ wherein R_{45} and R_{46} are each independently hydrogen, C_1-C_2alkyl, or R_{45} and R_{46} taken together form a 5-membered monocyclic ring;

z is 0 or 1;

e is 2, 3, 4, 5, 6 or 7;

h is 0, 1, 2 or 3;

u is 0, 1, 2, 3 or 4;

o is 0 or 1;

l is 0 or 1;

j is 0, 1, 2 or 3;

v is 0, 1, 2, 3 or 4;

w is 1, 2 or 3 as hereinbefore defined;

f is 1, 2, 3 or 4;

t is 0 or 1 as hereinbefore defined;

b is 0, 1 or 2;

q is 0 or 1as hereinbefore defined;

aa is 0 or 2;

X is O, S or NR_{90} wherein R_{90} is hydrogen, C_1-C_6alkyl, or



wherein R_{143} is hydrogen or alkyl;

each M and V is a group independently selected from hydrogen, halogen, C_1-C_6alkyl, C_1-C_6alkoxy, trifluoromethyl, hydroxy, phenyl, phenoxy, $-SO_2NH_2$ or



; or

$-NR_{48}R_{49}$ wherein R_{48} and R_{49} are each independently hydrogen or C_1-C_2alkyl;

each R_{31}, R_{32}, R_{33}, R_{34}, R_{35}, R_{36}, R_{37}, R_{38}, R_{39}, R_{40}, R_{68}, and R_{69} is independently hydrogen or C_1-C_6alkyl;

each R_{29}, R_{30} is independently hydrogen, phenyl or C_1-C_6alkyl;

each R_{83}, R_{84}, R_{86}, R_{87}, R_{88}, R_{89}, R_{92}, R_{93}, R_{98}, R_{99}, R_{94}, R_{95}, R_{100}, R_{101}, R_{103}, R_{104}, R_{105}, R_{106}, R_{108}, R_{109}, R_{110}, R_{111}, R_{113}, R_{114}, R_{115}, R_{116}, R_{117}, R_{118}, R_{119}, R_{120}, R_{122}, R_{123},

R_{124}, R_{125}, R_{127}, R_{128}, R_{130}, R_{131}, R_{133}, R_{134}, R_{135}, R_{136}, R_{137}, R_{138}, R_{139} and R_{140} is independently hydrogen or C_1-C_6alkyl;

each R_{63}, R_{64} and R_{65} is independently hydrogen, halogen, C_1-C_6alkyl or C_1-C_6alkoxy;

each R_{66} is independently hydrogen, hydroxy, C_1-C_6alkyl or C_1-C_6alkoxy;

Q is CH_2, CHOH or C=O;

X_5 is O or S;

each R_{67} is independently hydrogen or C_1-C_6alkyl;

R_{70} is hydrogen, C_1-C_6alkyl, halogen, nitro or a phenyl group optionally mono-substituted with C_1-C_6alkyl, halogen or trifluoromethyl;

R_{81} is hydrogen, C_1-C_6alkyl, or -CO_2C_1-C_6alkyl;

R_{91} is hydrogen, halogen, C_1-C_6alkyl or C_1-C_6alkoxy;

R_{96} is hydrogen, C_1-C_6alkyl or



wherein R_{145} and R_{146} are each independently hydrogen or C_1-C_6alkyl and b is 0, 1 or 2 as hereinbefore defined;

R_{97} is hydrogen or C_1-C_6alkyl;

each R_{102} is independently hydrogen, halogen, C_1-C_6alkyl or C_1-C_6alkoxy;

R_{107} is hydrogen or C_1-C_6alkyl;

each R_{121} is independently hydrogen, halogen, C_1-C_6alkyl or C_1-C_6alkoxy;

R_{127} is hydrogen or C_1-C_6alkyl;

R_{126} is C_1-C_6alkyl or benzyl;

R_{129} is hydrogen or C_1-C_6alkyl;

R_{132} is hydrogen, C_1-C_6alkyl, halogen or C_1-C_6alkoxy;

X_3 is O or -NR_{127} wherein R_{127} is hydrogen or

C_1-C_6alkyl;

X_4 is O, S or -NR_{143} wherein R_{143} is hydrogen or C_1-C_6alkyl;

R_{141} is hydrogen, C_1-C_6alkyl or amino;

R_{142} is benzyl or phenyl each of which may be optionally substituted with C_1-C_6alkyl, halogen or C_1-C_6alkoxy;

R_{144} is hydrogen or C_1-C_6alkyl;

R_{85} is hydrogen, C_1-C_6alkoxy, C_1-C_6alkyl, -CO_2C_1-C_6alkyl, $C(O)C_1$-C_6alkyl or a group selected from the following:

a)



b)



c)



d)



e)



f)



g)



h)



i)



j)



k)



wherein

j is 0, 1, 2 or 3 as hereinbefore defined;

w is 1, 2 or 3 as hereinbefore defined;

m is 0, 1 or 2 as hereinbefore defined;

e is 2, 3, 4, 5, 6 or 7 as hereinbefore defined;

each R_{147}, R_{148}, R_{150}, R_{151}, R_{152}, R_{153}, R_{156}, R_{157}, R_{159}, R_{160} R_{162} and R_{163} is independently hydrogen or C_1-C_6alkyl;

R_{149} is hydrogen, halogen, C_1-C_6alkyl, phenoxy, trifluoromethyl or trifluoromethoxy;

R_{155} is hydrogen, halogen or C_1-C_6alkyl;

R_{158} is hydrogen or C_1-C_6alkyl;

R_{161} is hydrogen or C_1-C_6alkyl;

R_{164} is hydrogen, halogen, C_1-C_6alkyl or trifluoromethyl;

R_{165} is hydrogen, C_1-C_6alkyl or halogen;

X_7 is O or S or -NR_{167} wherein R_{167} is hydrogen or C_1-C_6alkyl;

R_{166} is hydrogen or C_1-C_6alkyl;

or R_1 and R_2 are joined together to form a 5-, 6-, or 7-membered monocyclic saturated ring, and in which the ring is optionally mono- or di-substituted, the substituents independently selected from:

(1) C_1-C_6alkyl;

(2) –CO_2-(C_1-C_6alkyl);

(3) –$NR_{50}R_{51}$ wherein R_{50} and R_{51} are each independently hydrogen, C_1-C_6alkyl, or a phenyl group which is optionally mono- or disubstituted with substituents independently selected from C_1-C_6alkyl, halogen or trifluoromethyl;

(4) -C(O)phenyl wherein the phenyl group is optionally mono- or disubstituted with substituents independently selected from C_1-C_6alkyl, halogen or trifluoromethyl;

(5) –$(CH_2)_mOR_{52}$ wherein R_{52} is hydrogen or C_1-C_2alkyl or a phenyl group which is optionally mono- or disubstituted with substituents independently selected from C_1-C_6alkyl, halogen or trifluoromethyl, and m is 0, 1 or 2 as hereinbefore defined;

(6) –NR_{54}-COR_{53} wherein R_{54} is hydrogen or C_1-C_6alkyl and R_{53} is hydrogen or C_1-C_2alkyl ;

(7) =O;

(8) –CN;

(9)



(10)



(11)



(12)



(13)



(14)



(15)



(16)



(17)



wherein

b is 0, 1 or 2 as hereinbefore defined;

w is 1, 2 or 3 as hereinbefore defined;

t is 0 or 1 as hereinbefore defined;

i is 0, 1 or 2;

v is 0, 1, 2, 3 or 4 as hereinbefore defined;

k is 0 or 1 as hereinbefore defined;

c are 0, 1 or 2;

R_{167} is hydrogen or C_1-C_6alkyl;

each R_{55}, R_{56}, R_{58}, R_{59}, R_{169} and R_{170} is independently hydrogen or C_1-C_6alkyl;

each R_{57} is independently hydrogen, halogen or C_1-C_6alkyl;

each R_{60} is independently hydrogen, halogen or

C_1-C_6alkyl;

R_{61} and R_{62} are each independently hydrogen or C_1-C_6alkyl;

R_{168} is hydrogen, thienyl or furanyl;

R_{171} is hydrogen, C_1-C_6alkyl, halogen, trifluoromethyl or trifluoromethoxy;

or R_1 and R_2 are joined together to form a group of formula X;



(X)

or R_1 and R_2 are joined together to form the group of formula (Y)



(Y)

or R_1 and R_2 are joined together to form any of the following groups:

(a)



(b)



(c)



(d)



(e)



wherein

g is 1 or 2 as hereinbefore defined;

p is 0, 1 or 2 as hereinbefore defined;

R_{172} is hydrogen, C_1-C_6alkyl or C_1-C_6alkoxy;

R_{173} is hydrogen, C_1-C_6alkyl or phenyl optionally mono- or disubstituted with C_1-C_6alkyl or halogen; and

R_{82} is a substituent selected from the following groups:

(a) C_1-C_6alkyl optionally substituted with hydroxy;

(b) C_1-C_6alkenyl;

(c) C_1-C_6alkoxy;

(d) -$(CH_2)OC_1$-C_6alkyl;

(e)



wherein X_8 is -$(CR_{175}R_{176})_h$- or —$(CR_{177}$=$CR_{188})$—

wherein each R_{174} is independently hydrogen, C_1-C_6alkyl, halogen, trifluoromethyl, C_1-C_6alkoxy or benzyloxy;

h is 0, 1, 2 or 3 as hereinbefore defined;

each R_{175}, R_{176}, R_{177} and R_{178} is independently hydrogen or C_1-C_6alkyl; and

j is 0, 1, 2 or 3 as hereinbefore defined;

(f)



wherein X_9 is $-(CR_{180}R_{181})_j-$ or

$-(CR_{184}R_{185}CR_{186}=CR_{187})-$ or

$-(CR_{182}=CR_{183})-$

wherein

aa is 0 or 2 as hereinbefore defined;

R_{179} is hydrogen, C_1-C_6alkyl, halogen, trifluoromethyl, C_1-C_6alkoxy, benzyloxy or phenyl;

each R_{180}, R_{181}, R_{182}, R_{183}, R_{184}, R_{185}, R_{186} and R_{187} is independently hydrogen or C_1-C_6alkyl;

j is 0, 1, 2, or 3 as hereinbefore defined;

(g)



wherein w is 1, 2 or 3 as hereinbefore defined;

each R_{188} and R_{189} is independently hydrogen or C_1-C_6alkyl;

(h)



wherein

i is 0, 1 or 2 as hereinbefore defined;

each R_{190} is independently hydrogen, alkyl or halogen;

b is 0, 1, or 2 as hereinbefore defined;

each R_{191} and R_{192} is independently hydrogen or C_1-C_6alkyl;

(i)



wherein

a is 1, 2 or 3 as hereinbefore defined;

each R_{193} and R_{194} is independently hydrogen or C_1-C_6alkyl;

R_{195} is hydrogen, halogen or C_1-C_6alkyl;

(j)



wherein

e is 2, 3, 4, 5 or 6 as hereinbefore defined;

b is 0, 1 or 2 as hereinbefore defined;

each R_{196} and R_{197} is independently hydrogen or C_1-C_6alkyl;

each R_{198} and R_{199} is independently hydrogen or C_1-C_6alkyl;

(k)



(l)



wherein

each R_{200} and R_{201} is independently hydrogen or C_1-C_6alkyl;

w is 1, 2 or 3 as hereinbefore defined;

(m)



wherein

each R_{202}, R_{203}, R_{204} and R_{205} is independently hydrogen or C_1-C_6alkyl; and

w is 1, 2 or 3 is as hereinbefore defined;

(n)



wherein

C_1-C_6alkyl is optionally substituted with hydroxy;

each R_{206} and R_{207} is independently hydrogen or C_1-C_6alkyl; and

w is 1, 2 or 3 as hereinbefore defined;

(o)



wherein

each R_{208}, R_{209}, R_{210} and R_{211} is independently hydrogen or C_1-C_6alkyl;

w is 1, 2 or 3 as hereinbefore defined;

(p)



with the proviso that when n is 1; and y is 0; and R_3 is hydrogen or C_1-C_6alkyl;

and  is group (a),

and R is group:

(a) wherein R_4 is hydrogen, halogen or C_1-C_6alkyl, and R_1 is hydrogen or unsubstituted C_1-C_6alkyl, then R_2 cannot be a group of the following formula:

(a) wherein z is 0,

(b) wherein u is 0 and M is hydrogen, halogen, C_1-C_6alkyl, or trifluoromethyl,

(c) wherein o is 0,

(d) wherein l is 0,

(e) wherein j is 0,

(g) wherein v is 0, or

(i);

and also when R is the group of formula (a), R_1 and R_2 cannot be joined together to form the group of formula Y or a 5-, 6-, or 7-membered monocyclic ring

wherein said ring is unsubstituted or mono- or di-substituted with C_1-C_6alkyl;

(b) and R_1 is hydrogen or unsubstituted C_1-C_6alkyl, then R_2 cannot be a group of the following formula:

(a),

(b),

(d) wherein l is 0,

(k),

(l), or

(m) wherein Q is CH_2;

and also when R is the group of formula (b), R_1 and R_2 cannot be joined together to form a group of formula X or a group of formula Y or a 5-, 6-, or 7-membered monocyclic ring

wherein said ring is unsubstituted or mono- or di-substituted with C_1-C_6alkyl or



;

(d) and R_1 is hydrogen or unsubstituted C_1-C_6alkyl, then R_2 cannot be a group of the following formula:

(a),

(b) wherein u is 1,

(d),

(k),

(l), or

(m) wherein Q is CH_2;

and also when R is the group of formula (d), R_1 and R_2 cannot be joined together to form a group of formula X or a group of formula Y or a 5-, 6-, or 7-membered monocyclic ring

wherein said ring is unsubstituted or mono- or di-substituted with C_1-C_6alkyl or



;

(e) and R_1 is hydrogen or unsubstituted C_1-C_6alkyl, then R_2 cannot be a group of the following formula:

(a),

(b),

(d),

(k),

(l), or

(m) wherein Q is CH_2;

and also when R is the group of formula (e), R_1 and R_2 cannot be joined together to form a group of formula X or a group of formula Y or a 5-, 6-, or 7-membered monocyclic ring

wherein said ring is unsubstituted or mono- or di-substituted with C_1-C_6alkyl or



;

(f) and R_1 is hydrogen or unsubstituted C_1-C_6alkyl, then R_2 cannot be a group of the following formula:

(a),

(b),

(d),

(k),

(l), or

(m) wherein Q is CH_2;

and also when R is the group of formula (f), R_1 and R_2 cannot be joined together to form a group of formula X or a group of formula Y or a 5-, 6-, or 7-membered monocyclic ring

wherein said ring is unsubstituted or mono- or di-substituted with C_1-C_6alkyl or



;

(g) and R_1 is hydrogen or unsubstituted C_1-C_6alkyl, then R_2 cannot be a group of the following formula:

(a),

(b) wherein u is1,

(d),

(k),

(l), or

(m) wherein Q is CH_2;

and also when R is the group of formula (g), R_1 and R_2 cannot be joined together to form a group of formula X or a group of formula Y or a 5-, 6-, or 7-membered monocyclic ring

wherein said ring is unsubstituted or mono- or di-substituted with C_1-C_6alkyl or



;

(h) and R_1 is hydrogen or unsubstituted C_1-C_6alkyl, then R_2 cannot be a group of the following formula:

(a),

(b),

(d),

(k),

(l), or

(m) wherein Q is CH_2;

and also when R is the group of formula (h), R_1 and R_2 cannot be joined together to form a group of formula X or a group of formula Y or a 5-, 6-, or 7-membered monocyclic ring

wherein said ring is unsubstituted or mono- or di-substituted with C_1-C_6alkyl or



; or

(j), then R_1 and R_2 cannot be joined together to form a group of formula Y or a 5-, 6-, or 7-membered monocyclic ring

wherein said ring is unsubstituted or mono- or di-substituted with C_1-C_6alkyl.

47. The method of claim 46, wherein the central nervous system disorder is selected from Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders, Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders, Mood Disorders and Nausea.

48. The method of claim 47 wherein the Psychotic Disorder is Schizophrenia.

49. The method of claim 48 wherein the compound of formula IB is administered in conjunction with one or more dopamine D_1, D_2, D_4, D_5, or 5HT receptor antagonists.

50. A pharmaceutical composition comprising an effective amount of a compound of claim 1 with a pharmaceutically-acceptable carrier or diluent.

51. A pharmaceutical composition comprising an effective amount of a compound of claim 1 with a pharmaceutically-acceptable carrier or diluent in conjunction with one or more dopamine D_1, D_2, D_4, D_5 or 5HT receptor antagonists.

52. A depot pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 1, wherein the compound contains an acylated hydroxy group, or an acylated amino group.

53. The depot pharmaceutical composition of claim 52, wherein the hydroxy group is acylated, or the amino group is acylated with (C_4-C_{18})alkanoyl group or a (C_4-C_{18})alkoxycarbonyl group.

54. The composition of claim 52 which contains a pharmaceutically acceptable oil.

55. The composition of claim 54 wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cotton seed oil, corn oil, soybean oil, olive oil, and synthetic esters of fatty acids and polyfunctional alcohols.

56. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 52 sufficient to produce a long acting antipsychotic effect.

57. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 53 sufficient to product a long acting antipsychotic effect.

58. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 54 sufficient to produce a long acting antipsychotic effect.

59. A compound of claim 1 wherein one or more of the atoms contained therein is a radionuclide.

60. A compound of claim 59 wherein R is group (a), with a radiolabeled ^{14}C in the 3-position of the benzo[b]thiophene ring, R_4 is trifluoromethyl, s is 1, R_3 is hydrogen, n is 1, y is 0, and A is N.

61. A diagnostic method for monitoring neuronal functions in a mammal comprising

introducing into a mammal a radiolabeled compound according to claim 59.

62. The method of claim 61 wherein said diagnostic method is performed using single positron emission computed tomography.

63. A process for preparing a compound of formula I of claim 1 which comprises:

(a) reacting a compound of formula (II):



(II)

wherein R_3, g, y, R, A and n are as defined in formula I of claim 1;

with a compound of formula (III)



(III)

wherein "LG" is a suitable leaving group selected from chlorine, bromine, iodine and mesyl; and  is as defined in formula I of claim 1;

to provide a compound of formula (IV)



(IV)

(b) hydrolyzing a compound of formula (IV) to provide a compound of formula (V)



(V)

and (c) reacting a compound of formula (V) with a compound of formula (VI)



(VI)

wherein R_1 and R_2 are as defined in formula (I) of claim 1;

to provide the compound of formula (I).

64. A process for preparing compounds of formula I of claim 1 which comprises:

(a) reacting a compound of formula (VII)



(VII)

wherein "LG" is a suitable leaving group selected from chlorine, bromine, iodine and mesyl; and  , R_1 and R_2 are as defined in formula I of claim 1;

with a compound of formula (II)



(II)

wherein R_3, g, y, R, A and n are as defined in formula I of claim 1;

to provide th compound of formula (I).

65. A process for preparing a compound of formula (VIII)



(VIII)

comprising the steps of:

a) contacting a compound of formula (IX)



(IX)

with a reagent of formula (X)



(X)

to provide a compound of formula (XI)



(XI)

; and

(b) treating the compound of formula (XI) with triphenylphosphine followed by bromine to provide the compound of formula (VIII).

66. A process for preparing a compound of formula (XII)



(XII)

comprising the step of coupling a compound of formula (XIII)



(XIII)

with a compound of formula (XIV)



(XIV)

to provide the compound of formula (XII).

67. A method of treating renal dysfunction which comprises administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1.

68. The compound of claim 1 wherein R is (a).

69. The compound of claim 1 wherein R is (b).

70. The compound of claim 1 wherein R is (c).

71. The compound of claim 1 wherein R is (d).

72. The compound of claim 1 wherein R is (e).

73. The compound of claim 1 wherein R is (f).

74. The compound of claim 1 wherein R is (g).

75. The compound of claim 1 wherein R is (h).

76. The compound of claim 1 wherein R is (i).

77. The compound of claim 1 wherein R is (j).

78. The compound of claim 1 wherein R is (k).

79. The compound of claim 1 wherein R is (l).

80. The compound of claim 1 wherein R is (m).

81. The compound of claim 1 wherein R is (n).

82. The compound of claim 1 wherein R is (o).

83. The compound of claim 1 wherein R is (p).

84. The compound of claim 1 wherein R is (q).

85. The compound of claim 1 wherein R is (r).

86. The compound of claim 1 wherein R is (s).

87. The compound of claim 1 wherein R is (t).

88. The compound of claim 1 wherein R is (u).

89. The compound of claim 1 wherein R is (v).

90. The compound of claim 1 wherein R is (w).